1. Dapagliflozin's Impact on Ventricular Repolarization in patients with heart failure with reduced ejection fraction.
- Author
-
Ben Halima, A., Souissi, W., Emna, B., Ferchichi, O., and Kammoun, I.
- Abstract
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) added to optimal medical therapy have been shown to reduce the risk of cardiovascular death and recurrent heart failure (HF) hospitalization in HF patients. But whether SGLT2i reduce ventricular arrhythmias and sudden cardiac death (SCD) is controversial. Ventricular repolarization heterogeneity is associated with ventricular arrhythmias. We aimed to evaluate the effect of Dapagliflozin on the ventricular repolarization markers (VRM) in patients with HF with reduced ejection fraction (HFrEF). This retrospective study included patients referred to our cardiology department between February 2022 and June 2023 for assessment of HFrEF and who were on beta-blocker, angiotensin-converting enzyme inhibitor (ACE-I)/angiotensin receptor blocker (ARB) and mineralocorticoid receptor antagonist. They underwent before introduction of dapagliflozin and 6 months later electrocardiograms (ECG) with measurement of QT interval, QTc (corrected by Bazett formula), QT dispersion (QTd), QTc dispersion (QTc-d), Tpeak to Tend (Tp-e) interval, Tp-e/QT, and Tp-e/QTc ratios. A total of 50 patients in sinus rhythm were included. The mean age was 60.88 ± 11.36 years old, and 11 (22%) were female patients. The mean ejection fraction was 30.86 ± 7.2%. Diabetes, hypertension, and chronic kidney disease were reported in 48%, 30%, and 20% of the patients, respectively. We compared VRM before and after introduction of dapagliflozin and we noticed a significant decrease in QTc intervals (430.74 ± 33.81 ms vs. 408.74 ± 32.45 ms; P < 0.001), QT-d (54 ± 19.24 ms vs. 36.2 ± 11.8 ms; P < 0.001) and Tp-e interval (95.8 ± 24.83 ms vs. 74.8 ± 22.87 ms; P < 0.001). Following the introduction of dapagliflozin, we observed a significant increase in left ventricular ejection fraction (LVEF) (30.86 ± 7.2% vs. 38.93 ± 7.07%; P < 0.001). Additionally, left ventricular end-diastolic diameter and left ventricular end-systolic diameter decreased significantly (58.68 ± 7.05 mm vs. 56.28 ± 6.3 mm; P < 0.001, 46.7 ± 8.1 mm vs. 40.7 ± 7.82 mm; P < 0.001). In addition, study participants experienced an improvement in functional capacity. The addition of dapagliflozin to optimal medical therapy in HFrEF patients positively changes VRM (QT, QTc, QTd, Tp-e, and Tp-e/QTc). [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF